
Nipple adenoma is a rare benign tumor arising from the lactiferous ducts of the nipple and may clinically mimic malignant breast conditions such as Paget’s disease. Accurate diagnosis is often challenging, and histopathological confirmation is essential. A 37-year-old woman presented with a 10-month history of a red tumor on the right nipple accompanied by erosion and bloody nipple discharge. Imaging studies revealed no definite causative lesion; however, a subtle hypoechoic lesion within the nipple was noted on ultrasonography. A punch biopsy demonstrated benign proliferative glandular structures. Surgical excision was performed with complete removal of the nipple and partial resection of the areola. Histopathological examination showed ductal proliferation with a dual epithelial and myoepithelial cell layer without cytologic atypia or invasive features. Immunohistochemical staining for p63 confirmed the presence of myoepithelial cells. The postoperative course was uneventful, and no recurrence was observed at the 6-month follow-up. Nipple adenoma should be considered in patients presenting with nipple lesions. Histopathological and immunohistochemical evaluation is essential for accurate diagnosis and appropriate management, allowing differentiation from malignant conditions and avoidance of overtreatment.
Purpose: Gastric cancer is a major global health issue, especially in advanced stages with metastasis. However, anti-angiogenic treatments such as ramucirumab target vascular endothelial growth factor, yet the exact mechanisms behind hematogenous metastasis remain unclear. This study analyzed RNA sequencing data from TCGA to identify angiogenesis-related genes in metastatic gastric cancer.Methods: Patients were categorized into four metastasis types (non-metastasis, hematogenous, locoregional, and lymphatic) based on clinical data. cBioPortal was used to identify frequently mutated genes across five metastatic cancer studies. RNA sequencing and clinical data were obtained from the TCGA-STAD project. RNA expression levels were compared across metastasis groups using independent-samples t-tests, followed by false discovery rate adjustment for multiple comparisons.Results: RNA expression analysis was performed using a 132-gene analytical panel in the TCGA-STAD cohort. Among the 95-gene angiogenesis/metastasis-related genes represented in this panel, RAF1, ARID1A, ERBB3, FGFR3, BAP1, TSC2, and KDR showed nominal expression differences in comparisons involving the hematogenous metastasis group. None of these differences remained statistically significant after false discovery rate correction.Conclusion: In this exploratory analysis, several candidate genes with prior literature support showed nominal expression differences in comparisons involving hematogenous metastasis in gastric cancer. These findings are hypothesis-generating and require validation in independent cohorts and functional studies.
Purpose: Neoadjuvant chemoradiotherapy (NACRT) followed by esophagectomy is a standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Pathological response, assessed using tumor regression grade (TRG), is an established prognostic marker; however, evidence regarding its association with the pattern and timing of recurrence remains limited. This study evaluated recurrence patterns, timing of recurrence, and survival outcomes according to pathological tumor response following NACRT and esophagectomy for ESCC.Methods: We retrospectively analyzed 129 patients with ESCC who underwent NACRT followed by radical esophagectomy between January 2013 and June 2023. Pathological response was assessed according to the College of American Pathologists TRG system and categorized as TRG 0 (complete response), TRG 1 (near-complete response), TRG 2 (partial response), or TRG 3 (poor/no response). Recurrence patterns and timing, disease-free survival, and overall survival were compared across TRG categories.Results: Among 129 patients, 33 (25.6%) developed recurrence. Systemic recurrence was the most common pattern (16/33, 48.5%), followed by combined locoregional and systemic recurrence (9/33, 27.3%) and isolated locoregional recurrence (8/33, 24.2%). Patients with TRG 0 had the lowest proportion of isolated locoregional recurrence (16.7%), with systemic and combined recurrence accounting for 50.0% and 33.3%, respectively. In contrast, TRG 3 patients predominantly developed isolated locoregional recurrence (80.0%), with systemic recurrence occurring in 20.0%; all recurrences in this group occurred within 12 months, suggesting poorer local disease control.Conclusion: Poor pathological response was associated with earlier and predominantly locoregional recurrence, whereas favourable pathological response was associated with a greater proportion of systemic recurrence. These findings suggest that pathological tumor response may help inform postoperative risk stratification and guide individualized surveillance strategies in patients with ESCC.
Purpose: Minichromosome maintenance protein 2 (MCM2) is a key regulator of DNA replication and has been implicated in tumor progression. While previous studies have demonstrated its role in lung cancer stem cells (CSCs), its role in breast cancer remains unclear. This study aimed to investigate whether MCM2 regulates CSCs and epithelial-mesenchymal transition (EMT) in breast cancer.Methods: MCM2 expression and its prognostic significance were analyzed using public breast cancer datasets. MDA-MB-231 breast cancer cells were transfected with MCM2-specific small interfering RNA. CSC-associated markers and EMT-related proteins were evaluated by Western blotting. Sphere formation, migration, and invasion assays were performed to assess CSC properties and metastatic potential.Results: MCM2 expression was significantly elevated in breast cancer tissues and correlated with poor prognosis. Knockdown of MCM2 reduced the expression of CSC-associated markers, including ALDH1A1, Sox2, Oct4, and CD44. Functional assays showed that MCM2 suppression significantly decreased sphere-forming capacity, indicating impaired CSC properties. In addition, MCM2 knockdown increased E-cadherin expression while decreasing N-cadherin, Slug, Twist, and ZEB1 expression, suggesting inhibition of EMT. Migration and invasion abilities were also markedly reduced.Conclusion: Suppression of MCM2 was associated with reduced CSC and EMT-related phenotypes in MDA-MB-231 breast cancer cells.
Adenoid cystic carcinoma of the breast (ACCB) is a rare special-type carcinoma, accounting for <0.1% of breast malignancies. Despite its frequent triple-negative phenotype, ACCB typically demonstrates indolent behavior and a favorable prognosis. Owing to its rarity and overlapping radiologic and histopathological features, accurate diagnosis can be challenging. We retrospectively analyzed three cases of histologically confirmed primary ACCB diagnosed at a tertiary care center. Clinical presentation, imaging findings, histomorphology, immunohistochemistry, treatment, and follow-up data were reviewed. The patients were women aged 42–58 years, all presenting with a breast lump; one case showed Paget-like nipple changes. Imaging findings varied from benign-appearing cysts to Breast Imaging Reporting and Data System (BI-RADS) category 4 lesions. Histology revealed classic biphasic morphology with tubular, cribriform, and focal solid patterns with perineural invasion noted in one. Tumor cells consistently expressed c-KIT (CD117) and myoepithelial markers (p63/S100), lacked HER2 (human epidermal growth factor receptor 2) expression, and showed variable hormone receptor status. All tumors were low-grade (grade 1), ≤2 cm, with negative sentinel lymph nodes where assessed. Surgical excision with clear margins was performed in all cases, with adjuvant radiotherapy in one patient. No recurrence or metastasis was observed on follow-up. Primary ACCB requires accurate recognition to prevent misdiagnosis and overtreatment.